Cancer research moves fastest when we move together. This #WorldCancerResearchDay, we are proud to collaborate with leading academic medical centers, biopharma partners, and care teams. Together, we are uniting the oncology ecosystem around a single, vital goal: improving patient outcomes. Learn how we collaborate to advance precision medicine: tempus.co/4ACT3KX

#WorldCBCDx is right around the corner. Join our CSO, Kate Sasser and Said Francis, Chief Business Officer and General Manager of Individualized Neoantigen Therapies at @moderna_tx , for a fireside chat discussing how combining #NGS and advanced therapeutic platforms is accelerating the development of neoantigen therapies and personalized medicines, and has the potential to transform cancer care. Learn more: tempus.co/3TMFY0T

We are excited to announce an extension of our data license agreement with @RecursionPharma through November 2029, building on our shared mission to advance precision medicine using AI foundation models. As part of this expanded multi-year partnership, we have also entered into a new license agreement for Recursion’s proprietary RNA foundation model, TxFM. By combining our multimodal real-world dataset with novel foundation models, we are continuing to accelerate therapeutic discovery and bring better treatments to patients faster. Read on: tempus.co/4iZ1jyz

Understanding the complex immune landscape of platinum-resistant #ovariancancer (PROC) is critical to advancing targeted therapies. In a recent analysis featured in the Tempus Lens Library, researchers evaluated B7-H4 co-expression and PD-L1 prevalence in patients with PROC. By leveraging our real-world datasets, the study highlights how B7-H4 intersects with PD-L1 and other emerging antibody-drug conjugate (ADC) targets. Explore the full study and findings in the Lens Library: tempus.co/3V0l6Uf #PrecisionOncology

This #BloodCancerAwarenessMonth, we're proud to support @BloodCancerUtd's Dream Project in its mission to transform pediatric blood cancer care by empowering patients with their health data and fueling scientific breakthroughs.  Partnering on this project advances our shared commitment to precision medicine, particularly for rare conditions like pediatric blood cancer that urgently require high-quality, comprehensive data.

"Healthcare will likely be the biggest beneficiary of AI." Our Founder & CEO @lefkofsky joined @CNBC to share how intelligent diagnostics and data are unlocking personalized care at scale. Watch the interview: cnb.cx/473wxNr

We are expanding beyond targeted gene panels into whole-genome sequencing to create a deeper understanding of the role the genome plays in disease progression and treatment response, all toward the goal of improving patient outcomes. Read on: tempus.co/4xNr9Ke

More than 6 million Americans live with heart failure, and nearly half die within five years of diagnosis. Tempus has been selected by ARPA-H to build and clinically validate an autonomous AI agent designed to extend existing care teams and support patients with heart failure. By establishing seamless surveillance across both clinical and home-based data, the platform continuously monitors patients and helps support symptom management, medication adherence, virtual rehabilitation and care coordination. Learn more: tempus.co/46OITZI

Our founder and CEO @lefkofsky joined @FoxBusiness to discuss how our AI-enabled platform leverages multimodal real-world data to help clinicians tailor personalized treatment plans for patients. He also highlighted our strategic partnership with Merck, exploring how data-driven insights are advancing precision medicine, improving patient outcomes, and driving long-term efficiencies in healthcare costs. Watch below:

In a recent webinar, Olivier Harismendy, Ph.D., Vice President of Translational Data Science at Zentalis Pharmaceuticals, shared how his team utilized Tempus Lens and its integrated workspace to test complex hypotheses for their pipeline. Learn more about how industry leaders are using our integrated AI platform and multimodal data to accelerate research and power scientific breakthroughs: tempus.co/4qQMuQl

How do researchers go from a complex biological question to an actionable insight without being slowed down by disconnected tools? By bringing his data, code, and custom AI together in one seamless environment, Sebastià Franch-Expósito, Ph.D, Lead Computational Biologist at Tempus, uses Lens Workspaces to train his own AI agents on past research and code. This integration allows him to move from hypothesis to insight much faster, all in one environment. Request a demo: tempus.co/4ckVk2N

PTEN IHC, a laboratory-developed test performed by PathGroup, is now available via Tempus Hub as an add-on for patients with metastatic hormone-sensitive prostate cancer (mHSPC). This addition to our IHC portfolio reinforces our commitment to expanding multi-modal testing options, empowering physicians with the comprehensive insights needed to guide patient care. Learn more: tempus.co/3T0H3lh

At Tempus, our mission is to advance precision medicine by taking the guesswork out of healthcare. We are working to solve this challenge by:  💡 Filling the missing pieces: Connecting fragmented health records so researchers don't miss crucial patient survival signals. 💡Finding earlier answers: Looking beyond years-long survival tracking to identify reliable, earlier indicators of success. 💡Matching the right treatment to the right patient: Linking genetic and clinical data to ensure therapies reach the patients most likely to benefit.   A new whitepaper explores how smarter data is transforming oncology R&D: tempus.co/3SUaMfJ

Last chance to register for tomorrow's webinar which offers an inside look at our state-of-the-art Tokyo facility, current assay portfolio, and upcoming diagnostic developments. Attendees will also learn how we partner with international biopharma companies to optimize global clinical trials, and accelerate #CDx within the Japanese market. Register now: tempus.co/4ghK49I

We have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH (pulmonary hypertension), an AI-enabled software device that analyzes standard 12-lead electrocardiograms (ECGs) for signs associated with pulmonary hypertension. This is the third FDA-cleared device in our growing cardiovascular portfolio, expanding our suite of next-generation AI products aimed at identifying patients at risk for complex cardiac conditions. Learn more: tempus.co/4c2Z2hw

We're excited to see this incredible milestone and look forward to seeing how these advancements continue to improve outcomes for the patients who need them most.